SNAI peptide aptamer

SNAI peptide aptamer is a recombinant peptide aptamer developed by researchers at Meharry Medical College for the potential treatment of breast cancer, particularly aggressive and metastatic subtypes like triple-negative breast cancer (TNBC). The aptamer is a recombinant fusion protein containing thioredoxin, a tri-repeat of the SNAG and SLUG domains of SNAI2 (SLUG), and a membrane translocation motif (MTM; AAVLLPVLLAAP) to facilitate nuclear targeting. It is designed to inhibit the functions of the SNAI superfamily of zinc-finger transcriptional repressors, specifically SNAI1 (SNAIL) and SNAI2 (SLUG), which are key drivers of the epithelial-to-mesenchymal transition (EMT), cell migration, and metastasis. In vitro studies in human breast cancer cell lines (such as MDA-MB-231 and BT549) have demonstrated that the aptamer reduces invasive phenotypes, cellular migration, and anchorage-independent growth, while increasing sensitivity to anoikis.

Other names

SNAI2 peptide aptamerSNAI-2 peptide aptamerSNAI 2 peptide aptamer